Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732757 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 157
- Enrollment target
NCT01732757 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 157 participants.
The verdict
NCT01732757, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 157 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
Interventions
- DRUG Alcaftadine 0.25%
- DRUG Olopatadine 0.2%
- DRUG dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2012-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732757
The ClinicalTrials.gov registry entry for NCT01732757 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Alcaftadine 0.25% is the first listed.
NCT01732757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732757 about?
NCT01732757 is a clinical study titled "A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis". This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
What is the current status of trial NCT01732757?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 157 participants. The study started on 2012-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01732757?
The interventions under investigation include: Alcaftadine 0.25% (DRUG), Olopatadine 0.2% (DRUG), dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% (DRUG).
Who is sponsoring clinical trial NCT01732757?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.